Reportlinker Adds Prostate Cancer - France Drug Forecasts and Treatment Analysis to 2020

Dec 08, 2010, 13:09 ET from Reportlinker

NEW YORK, Dec. 8, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Prostate Cancer - France Drug Forecasts and Treatment Analysis to 2020

http://www.reportlinker.com/p0332353/Prostate-Cancer---France-Drug-Forecasts-and-Treatment-Analysis-to-2020.html

Prostate Cancer - France Drug Forecasts and Treatment Analysis to 2020

Summary

GlobalData's pharmaceutical report, "Prostate Cancer - France Drug Forecasts and Treatment Analysis to 2020" is an essential source of information and analysis on the French prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the French prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the French prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The scope of the report includes:

- An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

- Annualized French prostate cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.

- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.

- Competitor assessment including drug launch analysis and drug sales forecasts.

- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM (Life Cycle Management) activities and drug sales forecast.

- Analysis of unmet need in the market and target product profiles including opportunity for target products.

- Technology trends analytic framework to assess the strength of the pipeline.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.

- An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.

- Analysis of the current and future market competition in the French Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.

- Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. Merger and Acquisition (M&A analysis) which includes M&A deals by size and geography.

- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.

- Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics market in France.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

- Develop business strategies and perform superior market quantification analysis by

- Understanding the trends shaping and driving the French prostate cancer therapeutics market.

- Understanding the treatment preferences of physicians for each disease state and across treatment flow.

- Accessing market sizing forecasts and quantified growth opportunities in the French prostate cancer therapeutics market up to 2020.

- Quantifying the patient population in the French to better design product pricing and launch plans.

- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by

- Performing benchmarking analysis and growth opportunities against currently marketed products.

- Identifying market entry points based on safety, efficacy, and pricing parameters.

- Assessing competitiveness of products in the market by understanding the strengths and weaknesses of current competition.

- Develop and design your in-licensing and out-licensing strategies by

- Taking a comprehensive look at the disease pipeline and identifying the most promising paradigm-shifting products.

- Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.

- Track drug sales in the French prostate cancer therapeutics market from 2001 to 2020.

- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

- What's the next big thing in the French prostate cancer therapeutics market landscape? Identify, understand and capitalize.

1 Table of contents 3

1.1 List of Tables 6

1.2 List of Figures 7

2 Disease Overview 9

2.1 Overview 9

2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System 9

2.1.2 Jewett-Whitmore system 11

2.2 Epidemiology 11

2.3 Etiology 11

2.4 Symptoms 12

2.4.1 Localized or Locally Advanced Prostate Cancer 12

2.4.2 Metastatic Prostate Cancer 12

2.5 Diagnosis 12

2.5.1 Digital Rectal Examination 12

2.5.2 Prostate Specific Antigen Test 13

2.5.3 Transrectal Ultrasound 13

2.5.4 Prostate Biopsy 14

2.6 Pathology 14

2.6.1 Grading 14

2.7 Treatment 14

2.7.1 Watchful Waiting 14

2.7.2 Radiation therapy 15

2.7.3 Surgery 16

2.7.4 Hormone therapy 16

2.7.5 Chemotherapy Options 18

2.7.6 Other Treatments Being Studied 18

2.8 Treatment Guidelines 19

3 Market Characterization 20

3.1 France 20

3.1.1 Market Size 20

3.1.2 Drivers & Barriers 26

3.1.3 Impact on the Market 27

3.1.4 Forecasts 28

3.1.5 Drug Sales 35

3.1.6 Pricing & Reimbursements 39

4 Competitor Assessment 40

4.1 Strategic Competitor Assessment 40

4.1.1 Overview 40

4.1.2 Benchmarking 40

4.1.3 Current Competitor Assessment 44

4.2 Launch Analysis and Sales Forecasts 46

4.3 Product Profiles 47

4.3.1 Taxotere (docetaxel) 48

4.3.2 Casodex (Bicalutamide) 52

4.3.3 Zoladex (Goserelin) 57

4.3.4 Eligard (leuprolide acetate) 59

4.3.5 Firmagon (degarelix) 64

4.3.6 Novantrone (Mitoxantrone hydrochloride) 66

4.3.7 Emcyt (estramustine) 68

4.3.8 Trelstar (triptorelin) 70

4.3.9 Eulexin 71

4.3.10 Delestrogen 73

4.3.11 Gynodiol 75

4.3.12 Estrace tablet 76

4.3.13 Tace 77

4.3.14 Nilandrone 78

4.3.15 Premarin 79

4.3.16 Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol 80

5 Pipeline Assessment 81

5.1 Overview 81

5.2 Pipeline Analysis by Phase of Development 82

5.3 Pipeline by Mechanism of Action 83

5.4 Strategic Pipeline Assessment 84

5.4.1 Technology Trends Analytical Framework 84

5.5 Trends in Prostate Cancer Pipeline 85

5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs 85

5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline 85

5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 86

5.6 Partners in Research and Development 86

5.6.1 Licensing Agreements by Phase of Development 87

5.6.2 Licensing Agreements by Geography 90

5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 90

5.7 Most Promising Drugs' Profiles 91

5.7.1 Provenge (sipuleucel-T) 93

5.7.2 Jevtana (cabazitaxel) 95

5.7.3 Aflibercept (VEGF Trap) 97

5.7.4 Ipilimumab 99

5.7.5 Abiraterone Acetate (CB7630) 102

5.7.6 Zibotentan (ZD4054) 105

5.7.7 Sprycel (dasatinib) 107

5.7.8 MDV3100 110

5.8 Prostate Cancer Pipeline – Pre-clinical Phase 112

5.9 Prostate Cancer Pipeline – Phase I 114

5.10 Prostate Cancer Pipeline – Phase II 117

5.11 Prostate Cancer Pipeline – Phase III 125

5.12 Key Takeaway 128

6 Unmet Need and Target Product Profile 129

6.1 Unmet Need 131

6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy 131

6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 132

6.2 Opportunity for Target Product 133

6.3 Target Product Profile 135

6.3.1 Ideal Characteristics 135

6.3.2 Target Product Description 136

6.4 Key Takeaway 136

7 Strategic Assessment 137

7.1 Key Events Impacting the Future Market 137

7.2 Market Impact Analysis 138

7.3 Future Market Scenario 138

7.4 Company Analysis 139

7.4.1 Market Leadership 139

7.4.2 Future Players in the Market 140

7.5 Key Takeaway 140

8 Company Profiles 141

8.1 Sanofi-aventis 141

8.1.1 Business Description 141

8.1.2 Financial Overview 143

8.1.3 SWOT Analysis 143

8.1.4 Oncology Focus 147

8.2 Pfizer Inc. 148

8.2.1 Business Description 148

8.2.2 Financial Overview 149

8.2.3 SWOT Analysis 150

8.2.4 Oncology Focus 156

8.3 AstraZeneca 158

8.3.1 Business Description 158

8.3.2 Financial Overview 159

8.3.3 SWOT Analysis 160

8.3.4 Oncology Focus 164

8.4 Bristol-Myers Squibb 166

8.4.1 Business Description 166

8.4.2 Financial Overview 167

8.4.3 SWOT Analysis 167

8.4.4 Oncology Focus 172

8.5 Medivation 174

8.5.1 Business Description 174

8.5.2 SWOT Analysis 174

8.5.3 Oncology Focus 177

8.6 Takeda Pharmaceuticals 178

8.6.1 Business Description 178

8.6.2 SWOT Analysis 178

8.7 Dendreon Corporation 179

8.7.1 Business Description 179

8.7.2 SWOT Analysis 180

8.8 Johnson and Johnson 183

8.8.1 Business Description 183

8.8.2 SWOT Analysis 184

8.8.3 Oncology Focus 190

8.9 Auron Healthcare GmbH 191

8.9.1 Business Description 191

8.10 Oncogenex Pharmaceuticals, Inc. 192

8.10.1 Business Description 192

8.11 Agennix AG 192

8.11.1 Business Description 192

8.12 GTx, Inc. 192

8.12.1 Business Description 192

8.13 GlaxoSmithKline plc. 193

8.13.1 Business Description 193

8.13.2 Financial Overview 194

8.13.3 SWOT Analysis 194

8.13.4 Oncology Focus 200

9 M&A Analysis 202

9.1 Key Highlights 202

9.2 Key Deals' Analysis 203

9.2.1 Johnson & Johnson Acquires Cougar Biotechnology 203

9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals 203

9.2.3 Tolmar Holding Acquires QLT USA from QLT 204

9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics 204

9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co. 204

9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 204

9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax 204

9.2.8 GPC Biotech Merges with Agennix 204

9.2.9 Eli Lilly Acquires ImClone 205

9.2.10 BBM Holdings Acquires YM BioSciences 205

9.2.11 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals 205

9.3 M&A Deals by Geography 206

9.4 M&A Deals by Deal Size 206

10 Expert Opinion 207

10.1 France 207

11 Appendix 208

11.1 Market Definitions 208

11.2 Abbreviations 208

11.3 Research Methodology 210

11.3.1 Coverage 210

11.3.2 Secondary Research 211

11.3.3 Forecasting 211

11.3.4 Primary Research 214

11.3.5 Expert Panel validation 214

11.4 Contact Us 214

11.5 Disclaimer 214

11.6 Sources 2151.1 List of Tables

Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010 10

Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 13

Table 3: Prostate Cancer, France, Sales Value ($m), 2001-2009 20

Table 4: Prostate Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2001-2009 22

Table 5: Prostate Cancer Therapeutics Market, France, Patient Volume ('000s), 2001-2009 23

Table 6: Prostate Cancer Therapeutics Market, France, Treatment Usage Patterns ('000s), 2001-2009 24

Table 7: Prostate Cancer Therapeutics Market, France, Sales Value ($m), 2009-2020 28

Table 8: Prostate Cancer, France, Annual Cost of Therapy ($), 2009-2020 29

Table 9: Prostate Cancer Therapeutics Market, France, Patient Volume ('000s), 2009-2020 30

Table 10: Prostate Cancer Therapeutics Market, France, Treatment Usage Patterns ('000s), 2009-2020 32

Table 11: Prostate Cancer Therapeutics Market, France, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2010 36

Table 12: Prostate Cancer Therapeutics Market, France, Hormone-refractory Prostate Cancer Drug Sales ($m), 2009-2020 36

Table 13: Prostate Cancer Therapeutics Market, France, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2010 38

Table 14: Prostate Cancer Therapeutics Market, France, Hormone-dependent Prostate Cancer Drug Sales ($m), 2009-2020 38

Table 15: Prostate Cancer Therapeutics Market, France, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2010 38

Table 16: Prostate Cancer Therapeutics Market, France, Hormone-dependent Prostate Cancer Drug Sales ($m), 2009-2020 39

Table 17: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 41

Table 18: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010 42

Table 19: Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010 43

Table 20: Prostate Cancer, France, Benchmarking Major Marketed Products, 2010 47

Table 21: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 53

Table 22: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010 60

Table 23: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010 61

Table 24: Prostate Cancer, Global, Eligard, Regulatory Approval by Region 62

Table 25: Prostate Cancer, Global, Licensing Agreements, 2009-2010 89

Table 26: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 91

Table 27: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010 91

Table 28: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010 112

Table 29: Prostate Cancer, Global, Phase I Pipeline, August 2010 114

Table 30: Prostate Cancer, Global, Phase II Pipeline, August 2010 117

Table 31: Prostate Cancer, Global, Phase III Pipeline, August 2010 125

Table 32: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 135

Table 33: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 136

Table 34: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010 190

Table 35: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 191

Table 36: Prostate Cancer, Global, M&A Deals by Geography, 2010 2021.2

List of Figures

Figure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010 19

Figure 2: Prostate Cancer Therapeutics Market, France, Sales Value ($m), 2001-2009 20

Figure 3: Prostate Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2001-2009 22

Figure 4: Prostate Cancer Therapeutics Market, France, Patient Volume ('000s), 2001-2009 23

Figure 5: Prostate Cancer Therapeutics Market, France, Treatment Usage Patterns ('000s), 2001-2009 24

Figure 6: Prostate Cancer, France, Market Drivers and Restraints, 2009 26

Figure 7: Prostate Cancer, France, Historical Events Impact on the Market, 2010 27

Figure 8: Prostate Cancer Therapeutics Market, France, Sales Value ($m), 2009-2020 28

Figure 9: Prostate Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2009-2020 29

Figure 10: Prostate Cancer Therapeutics Market, France, Patient Volume ('000s), 2009-2020 30

Figure 11: Prostate Cancer Therapeutics Market, France, Treatment Usage Patterns ('000s), 2009-2020 32

Figure 12: Prostate Cancer Therapeutics Market, France, Future Market Drivers and Restraints, 2009-2020 34

Figure 13: Prostate Cancer Therapeutics Market, France, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 35

Figure 14: Prostate Cancer Therapeutics Market, France, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020 37

Figure 15: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010 44

Figure 16: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010 45

Figure 17: Prostate Cancer Therapeutics Market, France, Sales Forecast by Therapies, 2001-2020 46

Figure 18: Prostate Cancer, Global, Taxotere, Chemical Structure 48

Figure 19: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010 50

Figure 20: Prostate Cancer, France, Taxotere, Sales ($m), 2004-2020 51

Figure 21: Prostate Cancer, Global, Casodex, Chemical Structure 52

Figure 22: Prostate Cancer, Global, Casodex, LCM Activities, 1995-2010 55

Figure 23: Prostate Cancer, France, Casodex, Sales ($m), 1995-2020 56

Figure 24: Prostate Cancer, Global, Zoladex, Chemical Structure 57

Figure 25: Prostate Cancer, France, Zoladex, Sales Forecast ($m), 1998-2020 58

Figure 26: Prostate Cancer, Global, Eligard , Chemical Structure 59

Figure 27: Prostate Cancer, France, Leuprolide (Eligard), Sales Forecast ($m), 2001-6020 63

Figure 28: Prostate Cancer, Global, Firmagon, Chemical Structure 64

Figure 29: Prostate Cancer, France, Firmagon, Sales Forecast ($m), 2009-2020 65

Figure 30: Prostate Cancer, Global, Novatrone, Chemical Structure 66

Figure 31: Prostate Cancer, France, Mitoxantrone, Sales Forecast ($m), 2001-2020 68

Figure 32: Prostate Cancer, Global, Emcyt, Chemical Structure 68

Figure 33: Prostate Cancer, France, Estramustine, Sales Forecast ($m), 2001-2020 69

Figure 34: Prostate Cancer, Global, Trelstar, Chemical Structure 70

Figure 35: Prostate Cancer, Global, Eulexin, Chemical Structure 71

Figure 36: Prostate Cancer, Global, Delestrogen, Chemical Structure 73

Figure 37: Prostate Cancer, Global, Gynodiol, Chemical Structure 75

Figure 38: Prostate Cancer, Global, Estrace, Chemical Structure 76

Figure 39: Prostate Cancer, Global, Tace, Chemical Structure 77

Figure 40: Prostate Cancer, Global, Nilandrone, Chemical Structure 78

Figure 41: Prostate Cancer, Global, Premarin, Chemical Structure 79

Figure 42: Prostate Cancer, France, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020 80

Figure 43: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 81

Figure 44: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 82

Figure 45: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 83

Figure 46: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 84

Figure 47: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 85

Figure 48: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010 87

Figure 49: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 90

Figure 50: Prostate Cancer, France, Provenge, Sales Forecast ($m), 2012-2020 94

Figure 51: Prostate Cancer, France, Jevtana, Sales Forecast ($m), 2011-2020 96

Figure 52: Prostate Cancer, Global, Aflibercept, Chemical Structure 97

Figure 53: Prostate Cancer, France, Aflibercept, Sales Forecast ($m), 2014-2020 99

Figure 54: Prostate Cancer, France, Ipilimumab , Sales Forecast ($m), 2014-2020 101

Figure 55: Prostate Cancer, Global, Abiraterone, Chemical Structure 102

Figure 56: Prostate Cancer, France, Abiraterone, Sales Forecast ($m), 2013-2020 104

Figure 57: Prostate Cancer, Global, Zibotentan, Chemical Structure 105

Figure 58: Prostate Cancer, France, Zibotentan , Sales Forecast ($m), 2013-2020 107

Figure 59: Prostate Cancer, France, Sprycel , Sales Forecast ($m), 2013-2020 109

Figure 60: Prostate Cancer, Global, MDV3100, Chemical Structure 110

Figure 61: Prostate Cancer, France, MDV3100 , Sales Forecast ($m), 2013-2020 111

Figure 62: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 129

Figure 63: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 130

Figure 64: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 130

Figure 65: Prostate Cancer, France, Prostate Cancer, Opportunity and Unmet Need, 2010 131

Figure 66: Prostate Cancer, France, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 134

Figure 67: Prostate Cancer, France, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 134

Figure 68: Prostate Cancer, Global, Key Events Impacting the Future Market 137

Figure 69: Prostate Cancer, France, Implications for Future Market Competition, 2010 138

Figure 70: Prostate Cancer, Global, Future Players in the Market, 2010 140

Figure 71: Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 141

Figure 72: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010 142

Figure 73: Prostate Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010 143

Figure 74: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 148

Figure 75: Prostate Cancer, Global, Pfizer, SWOT Analysis 2010 150

Figure 76: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 156

Figure 77: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 157

Figure 78: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 159

Figure 79: Prostate Cancer, Global, AstraZeneca, SWOT Analysis 2010 160

Figure 80: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010 164

Figure 81: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 164

Figure 82: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 165

Figure 83: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 166

Figure 84: Prostate Cancer, Global, Company Bristol-Myers Squibb, SWOT Analysis, 2010 167

Figure 85: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 172

Figure 86: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 173

Figure 87: Prostate Cancer, Global, Medivation, SWOT Analysis 2010 174

Figure 88: Prostate Cancer, Global, Takeda Pharmaceuticals, SWOT Analysis 2010 178

Figure 89: Prostate Cancer, Global, Dendreon Corporation, SWOT Analysis 2010 180

Figure 90: Prostate Cancer, Global, Johnson and Johnson, SWOT Analysis 2010 184

Figure 91: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010 191

Figure 92: Prostate Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010 194

Figure 93: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 200

Figure 94: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 201

Figure 95: Prostate Cancer, Global, M&A Deals by Geography of Target Companies, 2010 206

Figure 96: Prostate Cancer, Global, M&A Deals by Deal Size, 2010 206

Figure 97: Prostate Cancer, France, Key Data Inputs from KOL Interviews, July 2010 207

Figure 98: GlobalData Market Forecasting Model 213

Companies mentioned

Sanofi-aventis

Pfizer Inc.

AstraZeneca

Bristol-Myers Squibb

Medivation

Takeda Pharmaceuticals

Dendreon Corporation

Johnson and Johnson

Auron Healthcare GmbH

Oncogenex Pharmaceuticals, Inc.

Agennix AG

GTx, Inc.

GlaxoSmithKline plc.

To order this report:

Drug and Medication Industry: Prostate Cancer - France Drug Forecasts and Treatment Analysis to 2020

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com